Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2018-08-31 Declaration of Voting R…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated August 31, 2018, announcing a change in the total number of outstanding shares and votes due to the exercise of stock options under an incentive program. This directly relates to a change in the company's capital structure (increase in shares and share capital). Based on the definitions, this aligns best with 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital structure changes. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a financing update (CAP) which usually implies raising external capital through debt or equity issuance rather than internal option exercises.
2018-08-31 Swedish
Number of shares and votes in Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated August 31, 2018, announcing a change in the number of outstanding shares and votes due to the exercise of warrants under incentive programs. This directly relates to a change in the company's capital structure (share count and share capital increase). Based on the definitions, the most appropriate category is 'Share Issue/Capital Change' (SHA), as it details an increase in the number of shares outstanding. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend notice (DIV) or a transaction in own shares (POS), as it results from warrant exercise, leading to new shares.
2018-08-31 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 1% confidence The document explicitly details a change in shareholding for a specific holder ('Stiftelsen Industrifonden') concerning Oncopeptides AB. Key phrases include 'Reason for major shareholding notification Sell', 'Shares', 'Voting rights', and the resulting 'Percentage' of ownership after the transaction. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2018-08-16 English
Anders Martin-Löf has been appointed as the new CFO of Oncopeptides
Board/Management Information Classification · 1% confidence The document is a press release announcing a specific change in senior personnel: the appointment of a new Chief Financial Officer (CFO), Anders Martin-Löf, and the departure of the previous CFO. This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2018-08-09 English
Oncopeptides utser Anders Martin-Löf som ny Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release from Oncopeptides AB announcing the appointment of a new Chief Financial Officer (CFO), Anders Martin-Löf, and noting the departure of the previous CFO. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The filing code for this is MANG. The document is short and appears to be an official announcement, not a comprehensive report.
2018-08-09 Swedish
Number of shares and votes in Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces a change in the number of shares and votes due to the exercise of warrants under incentive programs. This directly relates to a change in the company's capital structure or share count. The key phrases are 'number of shares and votes in Oncopeptides has changed as a result of exercise of warrants' and the resulting increase in outstanding shares and share capital. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA), which covers changes in capital structure and share counts, distinct from a general financing announcement (CAP) or a share repurchase (POS). The document is a direct notification of this change, not an announcement of a report.
2018-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.